Novaluzid

Quick links to important sections

Novaluzid

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novaluzid

Property Description
Active ingredients Aluminum Hydroxide, Magnesium Hydroxide
Form Oral Suspension, Chewable Tablet
Pharmacological Class Antacid (Gastric Acid Neutralizer)
General Purpose Rapid relief from acid indigestion and heartburn
Origin Synthetic Inorganic Compounds

Novaluzid: Classification and Active Components

Novaluzid is a well-known combination medicine globally recognized within the antacid pharmacological class, functioning specifically as a gastric acid neutralizer. Its formulation is distinguished by combining two synthetic inorganic salts: Aluminum Hydroxide and Magnesium Hydroxide. This dual-salt approach is a standard pharmaceutical strategy, clinically recognized for providing effective neutralization of stomach acid. The medicine is primarily positioned for adult patients seeking rapid, localized comfort from common upper gastrointestinal disturbances linked to gastric hyperacidity.

Compositional Design and Available Forms

The active components, Aluminum Hydroxide and Magnesium Hydroxide, are inorganic compounds rather than natural derivatives. Novaluzid is designed for oral administration and is supplied either as an oral suspension (liquid antacid) or as a chewable tablet. The design principle behind mixing these two ingredients is that the Aluminum-Magnesium combination achieves a balance in the digestive tract that is often preferred over single-salt antacids. This combination allows patients to choose the most convenient delivery method—the rapid-coating effect of the liquid suspension or the portability of the tablet—while guaranteeing a consistent level of acid-neutralizing capacity.

General Purpose of this Acid Neutralizer

The general purpose of Novaluzid is to provide rapid, symptomatic relief from the pain and discomfort caused by excess stomach acid. It achieves this through a mechanism of direct acid neutralization, an immediate chemical reaction that significantly elevates the gastric pH. This primary physical action translates into effective symptomatic alleviation of the painful, burning sensations associated with heartburn and a sour stomach. A typical use scenario involves managing acute symptoms of acid indigestion when they arise, providing prompt relief by managing the acid already present.

Regulatory References

  1. Aluminum Hydroxide and Magnesium Hydroxide Drug Information
  2. Aluminum/Magnesium Hydroxide vs. Calcium Carbonate for Heartburn

What side effects are possible with Novaluzid?

The safety information for Novaluzid (a combination of aluminum hydroxide and magnesium hydroxide) is derived from official government regulatory documents and is structured around known adverse reactions and specific patient restrictions.

Adverse Reactions

The most commonly documented adverse reactions involve the Gastrointestinal System. These reactions are typically categorized as uncommon or of unknown frequency in regulatory sources and primarily include changes in bowel habits:

  • Diarrhea (often associated with the magnesium component).
  • Constipation (often associated with the aluminum component).
  • Less frequently reported adverse events have included abdominal pain and hypersensitivity reactions.

Safety Restrictions and Cautionary Use

Official safety documents highlight critical limitations and risks associated with the drug's components, particularly concerning patient health status and concurrent medicine use:

Safety Domain Regulatory Statement
Population-Specific Risk Caution is mandatory in patients with Renal Impairment or Chronic Kidney Disease. Impaired kidney function may lead to the accumulation of both aluminum and magnesium in the body, which can cause severe toxicity, including hypermagnesemia and aluminum-related disorders (e.g., osteomalacia).
Drug Interactions The drug can bind to and interfere with the absorption of many other concurrently administered oral medicines, potentially reducing the efficacy of those other drugs. Administration times of Novaluzid and other oral medicines must be separated to manage this risk.
Duration of Use Safety profiles advise against prolonged or long-term administration due to the increased potential for systemic accumulation of the aluminum and magnesium components over time, especially in susceptible individuals.

These restrictions define the boundaries for the medicine’s safe use, emphasizing the necessity of caution in patients with underlying kidney conditions and when taking other medications.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes potential overdose presentations for this combination antacid (Aluminum Hydroxide and Magnesium Hydroxide) ranging from acute gastrointestinal effects to severe systemic toxicity. Acute overdose may present with symptoms such as diarrhea, abdominal pain, and vomiting. Ingestion of very high doses or prolonged exposure in high-risk patients can lead to severe complications.

Severity is primarily determined by the risk of systemic hyperion toxicity, including hypermagnesemia and hyperaluminemia. Severe hypermagnesemia is a documented concern that can progress to central nervous system depression, loss of deep tendon reflexes, and potentially lead to respiratory paralysis, hypotension, or cardiac arrest.

Mandated Emergency Actions

Action Focus Official Regulatory Statement
Urgent Medical Help Consult a doctor or go to a hospital straight away if overdose is suspected or if symptoms of bowel obstruction or severe toxicity manifest.
Overdose Management Management involves promoting ion clearance through rehydration and forced diuresis. Haemodialysis or peritoneal dialysis may be required in cases involving renal function deficiency.
Antidote Information No specific antidote is known; however, Intravenous Calcium Gluconate is used to antagonize the effects of severe magnesium toxicity.

Population-specific risk: Patients with renal function deficiency face a significantly higher risk of severe toxicity due to impaired clearance. Infants and the elderly are noted as having increased risk for intestinal obstruction (ileus) following large doses.

Therapeutic Uses of Novaluzid

Quick Facts

  • Provides symptomatic relief for heartburn.
  • Assists in the management of acid indigestion.
  • Used in therapeutic regimens for conditions like gastritis and duodenitis.

Novaluzid is an antacid medication used to address various conditions related to excess stomach acid. The established therapeutic uses of Novaluzid focus on providing temporary symptomatic relief.

It is applied in the management of symptoms associated with gastroesophageal reflux, commonly known as heartburn. This includes addressing the discomfort and burning sensation that may be present.

Additionally, Novaluzid is utilized for the short-term relief of acid indigestion (dyspepsia) and an upset or sour stomach. It forms part of the accepted supportive therapy for inflammatory conditions of the digestive tract lining, such as gastritis (stomach lining inflammation) and duodenitis (duodenal lining inflammation).

Healthcare providers may suggest this medication as an option when acid neutralization is required for patient comfort and to support the healing process. Novaluzid is often categorized as a combination antacid containing aluminum hydroxide and magnesium salts, which function as agents that address stomach acid.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility for Novaluzid Use: Regulatory Profile

Novaluzid (Aluminum Hydroxide and Magnesium Hydroxide) use is strictly defined by regulatory documents, which establish the populations and conditions that determine eligibility or exclusion.

Classification Eligibility Status (Regulatory)
Populations Allowed Adults and adolescents aged 12 years and older.
Contraindicated Populations Patients with severe renal impairment (kidney failure).
Individuals with hypophosphatemia (phosphate depletion).
Patients with known hypersensitivity to the active ingredients.
Condition-Based Restrictions Intestinal obstruction or undiagnosed abdominal pain (e.g., appendicitis).
Use is not recommended for periods exceeding 14 days without medical consultation.
Age-Related Rules Use is not established or not recommended for children under 12 years of age.
Pregnancy/Lactation Pregnancy: Use with caution, for a short duration only if clearly needed. Lactation: Generally considered acceptable due to low systemic absorption.

Eligibility constraints are driven by the risk of aluminum and magnesium accumulation in compromised renal function, and the risk of the aluminum component binding phosphate or causing constipation that could aggravate underlying gastrointestinal conditions. Use in mild-to-moderate renal impairment requires caution and monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Novaluzid's interaction profile is based on its components' effect on the gastrointestinal tract, primarily leading to the inhibition of oral drug absorption and changes in urinary pH. This necessitates mandatory administration constraints for co-administered medicines.

Medicinal Product Categories with Documented Interactions: Tetracycline- and Fluoroquinolone-Class Antibiotics, Oral Bisphosphonates, Oral Iron Salts, Thyroid Hormones, and Antiarrhythmics (Quinidine).

Interaction Classifications

Interaction-Related Restrictions: Co-administration is officially contraindicated with specific oral medicines, including Pazopanib and Raltegravir, due to a critical reduction in their systemic exposure. The combination with Citrates (found in certain foods and effervescent drugs) is restricted in renally impaired patients due to a documented significant increase in serum aluminum concentrations.

Timing-Based Interaction Rules: The regulatory labeling mandates timing separation for many co-administered oral medicines. Other oral drugs should generally be administered at least 2 hours before or 2 hours after the antacid dose to mitigate absorption interference.

Population-Specific Interaction Notes: Use is restricted in patients with advanced kidney disease due to the high risk of accumulation of both Aluminum and Magnesium and resulting systemic toxicity (hyperaluminemia, hypermagnesemia).

Official Interaction Statements

  • The antacid significantly reduces the absorption of numerous oral drugs, including antibiotics, Bisphosphonates (e.g., Alendronate), and Levothyroxine.
  • Co-administration with Quinidine increases its serum levels due to altered elimination.

Connection to the Overall Interaction Profile: The official regulatory documents define the interaction structure primarily as a pharmacokinetic absorption interference, which mandates strict timing-based administration constraints for most oral co-medications. The profile also documents a critical population-specific constraint and classifies specific combinations as contraindicated.

Mechanism of Action

Novaluzid functions as a selective inhibitor of the Calcineurin enzyme within T-lymphocytes. The drug initially binds to the intracellular receptor protein cyclophilin A, forming a complex. This drug-protein complex then physically engages and blocks the phosphatase activity of calcineurin.

This physical blockade prevents the dephosphorylation of the nuclear factor of activated T-cells ( NFAT). Because NFAT remains phosphorylated, its nuclear translocation is inhibited, preventing its entrance into the cell nucleus. The consequence of this intracellular cascade is a reduction in the transcription of genes encoding several pro-inflammatory cytokines, including IL-2, TNF-alpha, and IFN-gamma. This molecular action modulates T-cell activation and proliferation, altering the overall cellular immune response.

Dosage and Administration Information

How to Use Novaluzid

This section outlines the general principles of administering Novaluzid, a combination antacid.


Administration Protocol

Novaluzid, which contains Aluminum Hydroxide and Magnesium Hydroxide, is for oral administration. The medication is generally taken as needed for symptom relief, with a usage pattern defining a maximum of four times a day (QID). Dosing is typically scheduled 20 minutes to one hour after meals and at bedtime to correspond with periods of increased acid production.


Dosing and Preparation Rules

Property Instruction
Route of Administration Oral ingestion.
Standard Adult Dose 10 mL to 30 mL of the suspension or 1 to 4 chewable tablets per dose, depending on specific product concentration.
Maximum Duration Should be limited to short-term use and generally not taken for more than two weeks at the maximum dosage unless under professional direction.
Preparation The oral suspension must be shaken well immediately before measuring. Chewable tablets must be chewed thoroughly before swallowing.

Usage Constraints

The most important constraint for the use of Novaluzid is the required separation from other medications. The antacid should not be taken within 1 to 2 hours of other oral medicines, as the aluminum and magnesium components can significantly alter the absorption rate of co-administered drugs. Furthermore, caution is advised when using the medication in patients with renal impairment due to the potential for magnesium to accumulate in the body. Use in children under 12 years of age is not generally covered by standard adult dosing recommendations.

Recent Clinical Evidence

The research evidence for Novaluzid is centered on the types of studies that have examined its physical and chemical action as a gastric acid neutralizer for acute symptom patterns. The findings reported in scientific literature and by regulatory bodies help contextualize how the product was studied in conditions characterized by episodic or acute changes in symptom activity.


Evidence for the Relief of Heartburn Symptoms

Research relies on short-term randomized controlled trials (RCTs) and systematic reviews applied in research exploring how symptoms change over time in adults experiencing fluctuating or unstable symptoms. Studies focused on patient-reported outcomes describing perceived discomfort, specifically studying the time to and duration of patient-reported changes related to burning and pain. The evidence contributes to understanding symptom patterns by describing how the product was observed to influence the acidic environment of the stomach. The available evidence was assigned a High level for the evaluation of immediate, short-term symptom patterns.


Evidence for Acute Acid Indigestion (Dyspepsia)

For the symptomatic management of acid indigestion, studies were conducted during periods of increased symptom activity, focusing on episodes where symptoms become more noticeable. This research mainly included controlled trials that explored outcomes related to physical discomfort in adult study populations. Findings describe patterns observed in the studies related to the immediate effect on patient comfort. The certainty level was assigned High for the evaluation of acute, symptomatic changes during these episodes.


Known Research Gaps and Uncertainties

Research exploring long-term outcomes is relevant in evidence describing how symptoms are measured over time. However, follow-up durations were limited, and long-term effects are not fully established regarding the continuous use of this specific antacid combination. Additionally, data for certain groups remain insufficient, and research provides limited information regarding the product's use in children or specific groups with comorbidities.

Key Studies & References

  1. Aluminum hydroxide and magnesium hydroxide oral suspension - Drug Information

Frequently Asked Questions (FAQ)

Common questions about Novaluzid (FAQ)


Q: How quickly should Novaluzid start working after I take it?

According to the official product information, antacids are designed to neutralize stomach acid on contact. The mechanism of action, direct neutralization, is intended to provide rapid symptomatic relief.


Q: How long does the relief from heartburn last after taking Novaluzid?

Regulatory information indicates that antacids like Novaluzid are considered short-acting relief options. The duration of the neutralizing effect generally depends on the rate at which the contents empty from the stomach.


Q: Can Novaluzid be taken on an empty stomach?

Official administration instructions typically recommend taking this medication after meals or at bedtime to align with periods of increased acid production. The neutralizing effect may be prolonged when the medication is taken with or after food.


Q: Does Novaluzid neutralize stomach acid or just reduce its production?

Novaluzid works by the direct neutralization of stomach acid, which is a chemical reaction that immediately reduces the acid already present. It is classified as an antacid and works by direct neutralization; it does not reduce the production of new stomach acid.


Q: How is Novaluzid's mechanism of action different from PPIs (proton pump inhibitors)?

Novaluzid provides immediate relief by neutralizing the acid in the stomach. PPIs (Proton Pump Inhibitors) work by blocking the mechanisms that produce new stomach acid, which is a different action than neutralization.


Q: Can Novaluzid cause rebound acidity when stopped?

The regulatory label advises against using this antacid continuously for more than two weeks. While rebound hyperacidity is a theoretical effect with some antacids, it is not typically listed as a common adverse reaction for this specific combination. For self-treatment, use is generally recommended only for short periods.


Q: Is Novaluzid safe to take every day for occasional heartburn?

The regulatory label advises limiting the use of the maximum dosage to no more than two weeks. For self-treatment, the medication is intended for short-term use, and prolonged daily use is not covered by the standard guidelines.


Q: Is it normal to feel a chalky taste after chewing Novaluzid tablets?

Yes, some regulatory-approved versions of this antacid combination list an unpleasant or chalky taste as a possible adverse reaction. This is generally due to the taste profile of the active ingredients, Aluminum and Magnesium salts.


Q: What should I do if I forget to take my scheduled Novaluzid dose?

Information regarding a missed dose is included in the patient instructions found on the official product label. If there are questions about a missed dose, consulting the official label or a healthcare professional is recommended.


Q: Are there any specific foods or drinks that should be avoided when taking Novaluzid?

Official warnings specifically caution against combining this antacid with products containing Citrates. Citrates are found in many fruit juices and effervescent (fizzy) medicines. This combination with Citrates can increase aluminum absorption.


Q: What is the recommended storage method for Novaluzid tablets?

Official regulatory documents recommend that Novaluzid tablets be stored at Controlled Room Temperature (typically 20 C to 25 C). The product should be kept in its original container, tightly closed, and protected from excess heat and moisture.


Q: Is Novaluzid available in liquid or suspension form?

Yes, according to the official product label, this combination antacid is available for oral administration in both an oral suspension (a liquid form that must be shaken) and as a chewable tablet.


Q: Are there any known allergic reactions to the ingredients in Novaluzid?

Yes, regulatory documents caution that severe allergic reactions, known as hypersensitivity reactions, are possible. Signs of an allergic reaction may include rash, hives, or swelling of the face or throat, and are generally addressed in the core safety warnings.


Q: Does Novaluzid contain sugar or artificial sweeteners?

While the exact ingredients can vary by product, many regulatory-approved versions of this combination antacid are formulated to be sugar-free. These versions often use artificial sweeteners, such as saccharin sodium or sorbitol, as substitutes.


Q: Are there different flavors of Novaluzid tablets available?

Yes, the official labels for different versions of this combination antacid often list various flavorings, such as Cherry and Peppermint, among the inactive ingredients.


Q: Does Novaluzid have an expiration date I should look out for?

Yes, the official labeling for Novaluzid states that the medicine should not be used after the expiry date.


Q: Can Novaluzid be crushed or mixed with water instead of chewed?

The chewable tablets are explicitly instructed to be chewed thoroughly before swallowing. Crushing or mixing is not the directed administration method and is required to ensure the proper immediate action in the stomach, as directed by the label.


Q: Is Novaluzid available without a prescription everywhere?

In many countries, this combination antacid is classified by regulatory authorities as an Over-the-Counter (OTC) drug. This means it can typically be purchased without a formal prescription.


Q: Does Novaluzid help with gas or bloating?

This specific combination of aluminum and magnesium hydroxide is primarily indicated for heartburn and acid indigestion. However, some regulatory-approved products may contain an additional anti-gas ingredient like simethicone, which is indicated for the relief of pressure and bloating.


Q: Why do some people feel immediate relief when chewing Novaluzid?

The relief is rapid because the direct neutralization mechanism is designed to begin immediately when the active ingredients contact the gastric acid.


Q: Is Novaluzid considered a first-line treatment for mild indigestion?

Yes, according to prevailing clinical and regulatory guidelines, antacids are widely recognized as the primary (first-line) choice for the symptomatic management of mild, occasional heartburn and acid indigestion.


Q: Are there any specific mineral deficiencies that Novaluzid could potentially cause over time?

Official warnings note that the prolonged use of aluminum-containing antacids may interfere with the body's mineral balance. This can potentially lead to hypophosphatemia (low phosphate levels) due to the binding of phosphate in the digestive tract.


Q: Can Novaluzid cause headaches as a side effect?

Headaches are not listed among the most common adverse reactions reported in the core regulatory documentation for this antacid combination. The most frequently documented side effects involve changes in bowel habits.


Q: Do you need to drink water after chewing Novaluzid?

Patient instructions for the chewable tablets often advise following the dose by drinking a full glass of water. This step is included in the patient instructions to assist with swallowing and distribution.


Q: Are there generic versions of Novaluzid available under different names?

Yes, this combination of aluminum hydroxide and magnesium hydroxide is a standard formulation sold globally under many different generic and branded names. Examples include products marketed as Maalox, Mylanta, and Gelusil.

How should Novaluzid be stored and disposed of?

The storage and disposal of Novaluzid (Aluminum Hydroxide/Magnesium Hydroxide) must strictly follow official regulatory guidelines to maintain its stability and ensure safety.

Storage Requirements

Item Official Storage Statement
Temperature Range Store at Controlled Room Temperature (20 C to 25 C) and away from excess heat.
Handling Constraints Do not freeze the oral suspension or expose it to excess moisture. Do not store the medicine in a bathroom.
Container Integrity Keep the product in the original container and maintain the container tightly closed to protect the contents.
Child Safety Keep out of the sight and reach of children for household storage safety.

Disposal Instructions

Expired or unused Novaluzid should not be flushed down the toilet. The preferred method for discarding the product is using an authorized drug take-back program. If a take-back program is unavailable, mix the medicine with an undesirable substance (such as used coffee grounds) and place the mixture in a sealed container before disposal in the household trash, as specified by the FDA.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Novaluzid found in:

A-Z Index: